Abstract:Introduction: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing the potential value of a combination therapy are currently limited. We therefore investigated cardiorenal protection of respective mono- and combination therapy in a preclinical model of hypertension-induced end-organ damage. Methods: Cardiovascular (CV) morbidity and mortality were studied in hypertensive, N(ω)-nitro-L-arginine methyl ester-treated, renin-transgenic (mRen2)27 rats. Rats (10- to 11-week-old females, n = 13–17/group) were treated once daily orally for up to 7 weeks with placebo, finerenone (1 and 3 mg/kg), empagliflozin (3 and 10 mg/kg), or a combination of the respective low doses. Key outcome parameters included mortality, proteinuria, plasma creatinine and uric acid, blood pressure, and cardiac and renal histology. Results: Placebo-treated rats demonstrated a 50% survival rate over the course of 7 weeks. Drug treatment resulted in variable degrees of survival benefit, most prominently in the low-dose combination group with a survival benefit of 93%. Monotherapies of finerenone or empagliflozin dose-dependently reduced proteinuria, while low-dose combination revealed an early, sustained, and over-additive reduction in proteinuria. Empagliflozin induced a strong and dose-dependent increase in urinary glucose excretion which was not influenced by finerenone coadministration in the combination arm. Low-dose combination but not respective low-dose monotherapies significantly reduced plasma creatinine and plasma uric acid after 6 weeks. Treatment with finerenone and the low-dose combination significantly decreased systolic blood pressure after 5 weeks. There was a dose-dependent protection from cardiac and kidney fibrosis and vasculopathy with both agents, while low-dose combination therapy was more efficient than the respective monotherapy dosages on most cardiorenal histology parameters. Discussion/Conclusions: Nonsteroidal MR antagonism by finerenone and SGLT2 inhibition by empagliflozin confer CV protection in preclinical hypertension-induced cardiorenal disease. Combination of these 2 independent modes of action at low dosages revealed efficacious reduction in important functional parameters such as proteinuria and blood pressure, plasma markers including creatinine and uric acid, cardiac and renal lesions as determined by histopathology, and mortality indicating a strong potential for combined clinical use in cardiorenal patient populations.

Reno-protective effect of fenofibrate and febuxostat against vancomycin-induced acute renal injury in rats: Targeting PPARγ/NF-κB/COX-II and AMPK/Nrf2/HO-1 signaling pathways

Rutin Attenuates Vancomycin-Induced Nephrotoxicity By Ameliorating Oxidative Stress, Apoptosis, And Inflammation In Rats

N-acetylcysteine Ameliorates Vancomycin-induced Nephrotoxicity by Inhibiting Oxidative Stress and Apoptosis in the in Vivo and in Vitro Models

Vinpocetine Attenuates 5-Fluorouracil-Induced Renal Intoxication by Regulating Nrf2/ARE, NF-κB/TLR4, and NLRP3/ASC/Caspase-1 Signals in Rats

Suppression of glomerular damage and apoptosis and biomarkers of acute kidney injury induced by acetaminophen toxicity using a combination of resveratrol and quercetin

Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3/TLR4, Sirt-1/NF-κB/TGF-β signaling Pathways, and miR-23b-3p, miR-181a-5b expression

Oxyresveratrol and/or Dapagliflozin Attenuate Doxorubicin-Induced Nephrotoxicity via Modulation of PPAR-γ/Nrf-2/HO-1, NF-κB/TNF-α/Keap-1, and Bcl-2/Caspase-3/ATG-5 signaling pathways in rats

Vitamin C Attenuates Vancomycin Induced Nephrotoxicity Through the Reduction of Oxidative Stress and Inflammation in HK-2 Cells.

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS)

Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats

Protective effects of Fenofibrate on renal ischemia-reperfusion injury in rats

Vitamin C Reduces Vancomycin-Related Nephrotoxicity Through the Inhibition of Oxidative Stress, Apoptosis, and Inflammation in Mice.

Protective effects of royal jelly and Echinacea against moxifloxacin-induced renal and hepatic injury in rats

Sildenafil and furosemide nanoparticles as a novel pharmacological treatment for acute renal failure in rats

Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein

Amentoflavone Mitigates Cyclophosphamide-Induced Pulmonary Toxicity: Involvement of -SIRT-1/Nrf2/Keap1 Axis, JAK-2/STAT-3 Signaling, and Apoptosis

Modulation of miR-205/ EGLN2 by rosuvastatin mitigates colistin-induced nephrotoxicity in rats: Involvement of ATF4/ CHOP and Nrf2 pathways

Rutin Attenuates Vancomycin‐induced Renal Tubular Cell Apoptosis Via Suppression of Apoptosis, Mitochondrial Dysfunction, and Oxidative Stress

The preventive effect of Gastrodia elata Blume extract on vancomycin-induced acute kidney injury in rats

Chlorogenic Acid Prevents Vancomycin‐induced Nephrotoxicity Without Compromising Vancomycin Antibacterial Properties